Skip to content

Bristol-Myers Squibb BMY Other Income (Expense)

Other Income (Expense) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$331M-209%
Incyte logo
IncyteINCY
$6.28M-14.1%
Gilead Sciences logo
Gilead SciencesGILD
$235M+172%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$4.61M+12.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$53.4M+700%
Cytokinetics logo
CytokineticsCYTK
$11.02M-19.6%

Other financials

Income statement

See full
Revenue$13.0B+5.7%
Gross profit$9.2B+3.9%
Net income$3.3B+153%
EPS (diluted)$1.62+153%

Balance sheet

See full
Cash & equivalents$8.7B-30.8%
Total debt$43.3B-12.3%
Total equity$22.3B+28.0%
Total assets$87.6B-7.4%

Cash flow

See full
Operating cash flow$3.4B-13.4%
CapEx$305.0M-15.5%
Free cash flow$3.1B-13.2%

Valuation

See full
Market cap$129.88B+36.2%
Enterprise value$164.48B+24.5%
P/E14×-5.2×
P/S2.6×+0.6×

Profitability

See full
Gross margin70.2%-0.1pp
Net margin18.9%+8.4pp
FCF margin23.3%-7.3pp

Returns & leverage

See full
Return on equity46.7%+17.8pp
Debt / equity1.9×-0.9×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bristol-Myers Squibb's other income (expense)?
Bristol-Myers Squibb (BMY) reported other income (expense) of $61M in Q2 2026.
How has Bristol-Myers Squibb's other income (expense) changed year-over-year?
Bristol-Myers Squibb's other income (expense) increased by 112.3% year-over-year, from -$494M to $61M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.